908 Devices Inc. (MASS)
| Market Cap | 253.06M |
| Revenue (ttm) | 56.20M |
| Net Income (ttm) | 19.49M |
| Shares Out | 37.38M |
| EPS (ttm) | 0.54 |
| PE Ratio | 12.29 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 179,817 |
| Open | 6.68 |
| Previous Close | 6.74 |
| Day's Range | 6.62 - 6.77 |
| 52-Week Range | 4.20 - 9.34 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 12.00 (+77.25%) |
| Earnings Date | May 12, 2026 |
About MASS
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for MASS stock is "Buy" and the 12-month stock price target is $12.0.
News
908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the appointment of Kola Otitoju as its Chief Business ...
908 Devices Transcript: Sidoti March Small-Cap Virtual Conference
The company completed a strategic transformation, focusing on handheld analytical devices and expanding its product portfolio, resulting in 18% revenue growth and improved margins in 2025. New products like VipIR and XplorIR, along with recurring revenue and international expansion, are expected to drive 15%-20% growth in 2026.
908 Devices to Present at the Sidoti Small Cap Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices Transcript: Leerink Global Healthcare Conference 2026
Demand is rising due to global unrest and increased defense spending, with international revenues growing and robust U.S. government funding. Product innovation and recurring revenue are driving growth, while margin improvements and strategic investments support a path to profitability by 2027.
908 Devices Transcript: TD Cowen 46th Annual Health Care Conference
Reported 18% revenue growth and positive adjusted EBITDA, driven by handheld detection tools and strong state/local demand. VipIR and other products are fueling 2026 guidance of 15–20% growth, with recurring revenue and software initiatives like TeamLeader set to enhance predictability.
908 Devices Earnings Call Transcript: Q4 2025
Q4 and full year 2025 saw strong revenue growth, margin expansion, and a return to positive Adjusted EBITDA, driven by FTIR product adoption, recurring revenue, and operational efficiencies. 2026 guidance projects 15%-20% revenue growth, with continued focus on innovation and profitability.
908 Devices Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Revenue Outlook
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices to Participate in Investor Conferences in March
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices Enhances MX908 Usability and Adds New Drug Targets
BURLINGTON, Mass.--(BUSINESS WIRE)-- #chemicalID--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces new capabilities for its handheld MX908 ...
908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech...
908 Devices Transcript: Stephens Annual Investment Conference
A major transformation has refocused the business on handheld chemical detection for public safety and defense, driving 16% YTD revenue growth and improved margins. New product launches, strong state/local sales, and robust recurring revenue support a 20%+ growth outlook for 2026, with key catalysts including equipment modernization, NextGen MX908, and the DOD AFCAD program.
908 Devices Transcript: Stifel 2025 Healthcare Conference
Q3 saw strong revenue and portfolio expansion following a major acquisition and divestiture, with a focus on handheld detection devices. Growth is driven by state/local demand, new product launches, and government partnerships, with profitability and 20% growth targeted for 2026.
908 Devices Earnings Call Transcript: Q3 2025
Q3 revenue was $14M, down 4% YoY but up 8% sequentially, with strong FTIR device demand and improved adjusted EBITDA loss. 2025 guidance remains $54–$56M, targeting positive adjusted EBITDA in Q4, though ~$4M in Q4 revenue is at risk if government delays persist.
908 Devices Reports Third Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applicatio...
908 Devices to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applicatio...
United States Coast Guard Purchases 908 Devices' Handheld Mass Spec Devices for Chemical Threat Identification
BOSTON--(BUSINESS WIRE)-- #CoastGuard--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that the United States Coast Guard purchased 23 of ...
908 Devices to Report Third Quarter 2025 Financial Results on November 10, 2025
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applicatio...
United States Marine Corps Purchases 908 Devices' XplorIR Gas Identification Devices
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that the United States Marine Corps CBRNE Installation and Protec...
908 Devices Transcript: Canaccord Genuity’s 45th Annual Growth Conference
Transitioned to a focused public safety and defense tech company, expanding its handheld product portfolio and strengthening financials. Projecting accelerated growth, driven by global security needs, new product launches, and robust funding, with profitability targeted for 2026.
908 Devices Earnings Call Transcript: Q2 2025
Q2 2025 saw 14% revenue growth, record device placements, and improved adjusted EBITDA loss, with strong momentum from new product launches and favorable legislative funding. Guidance for 2025 was raised, targeting adjusted EBITDA positivity by Q4 and over 20% revenue growth in 2026.
908 Devices Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Outlook
BOSTON--(BUSINESS WIRE)-- #VipIR--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech a...
908 Devices Appoints Dr. Brandi Vann, former U.S. Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors
BOSTON--(BUSINESS WIRE)-- #CBRN--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Dr. Brandi Vann to serve on its Boa...
908 Devices to Participate in the Canaccord Genuity 45th Annual Growth Conference
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applicatio...
908 Devices to Report Second Quarter 2025 Financial Results on August 5, 2025
BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applicatio...